Home
News
Videos
Podcasts
Slides
Visual Abstracts
Topics
Conferences
- SCAI 2018
- ACC 2018
- AHA 2017
- ESC 2017
- SCAI 2017
- ACC 2017

Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis – The PRECISION Trial

By Usama Nasir, M.D. on April 1, 2018

Source: NEJM

t f

LAA Closure Associated With Less Bleeds vs. Oral Anticoagulation Post AF Ablation: OPTION

Key Takeaways: The OPTION TRIAL assessed the safety and efficacy of WATCHMAN FLX in a… Continue Reading

By Joseph Kim
November 19, 2024

Optimization of GDMT Very Modest but Increased Use of MRAs with Audit and Feedback: PHARM-HF A&F Study

Key Points: Over 6 million people in the US live with heart failure (HF), but… Continue Reading

By Dami Aladesanmi
November 19, 2024

A SUMMIT Analysis: Tirzepatide Reduces End Organ Damage in Patients with Obesity and HFpEF

Key Points SUMMIT, a randomized control trial of tirzepatide versus placebo in patients with HFpEF… Continue Reading

By Lucas Marinacci
November 19, 2024

Create an Account

CLICK TO REGISTER

Cardiology Now News is sponsored by the Baim Institute for Clinical Research and produced by the PERFUSE Study Group. Baim and PERFUSE are academic research organizations led by world class cardiovascular clinical trialists and opinion leaders.

Receive the latest news, interviews, podcasts directly to your inbox

Leave a Reply Cancel reply

More from

LAA Closure Associated With Less Bleeds vs. Oral Anticoagulation Post AF Ablation: OPTION

Optimization of GDMT Very Modest but Increased Use of MRAs with Audit and Feedback: PHARM-HF A&F Study

A SUMMIT Analysis: Tirzepatide Reduces End Organ Damage in Patients with Obesity and HFpEF